Recombinant Human DLL4 Fc Chimera GMP Protein, CF

The binding activity of Recombinant Human DLL4 GMP Protein (Catalog # BT-DLL4-GMP) was measured in a functional ELISA with Recombinant Human Notch-1 Protein. Three independent lots were tested for binding activity and plotted on the same graph to show lot-to-lot consistency of GMP DLL4 protein.

Equivalent binding activity of GMP (Catalog # BT-DLL4-GMP) and RUO (BT-DLL4) grades of Recombinant HumanDLL4 as measured in a functional ELISA with Recombinant Human Notch-1 Protein (orange and red, respectively).

2 μg/lane of Recombinant Human DLL4 Fc Chimera GMP Protein (Catalog # BT-DLL4-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 89-98 kDa and 180-200 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human DLL4 Fc Chimera GMP Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Recombinant Human DLL4 Fc Chimera GMP (Catalog # BT-DLL4-GMP) binds to Recombinant Human Notch-1 Fc Chimera (Catalog # 3647-TK) with an ED₅₀ of 2.00-20.0 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human DLL4 protein
  

  Human DLL4 (Ser27-Pro524) Accession # Q9NR61.1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

  
  Manufactured and tested under cGMP guidelines.
• N-terminal Sequence: Ser27-Gly-Val-Phe-Gln-Leu-Gln-Leu-Gln-Glu
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: GMP Recombinant Proteins
• Purity: >95%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 81 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 89-98 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in HBS and Tween®-80 with Trehalose.
• Purity: >95%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in sterile water.

Notes

Full terms and conditions of sale can be found online in the Protein Sciences Segment T&Cs at: Terms & Conditions.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human DLL4 Fc Chimera GMP Protein, CF

• Delta 4 precursor
• delta 4
• delta ligand 4
• delta4
• delta-like 4 (Drosophila)
• delta-like 4 homolog (Drosophila)
• delta-like 4 homolog
• delta-like 4 protein
• delta-like protein 4
• DLL4
• Drosophila Delta homolog 4
• hdelta2
• MGC126344
• notch ligand delta-2
• notch ligand DLL4

Background

Delta-like protein 4 (DLL4) is a type I membrane protein belonging to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Notch signaling is an evolutionarily conserved pathway that controls cell fate and is required in multiple developmental processes including vascular development, hematopoiesis, somatogenesis, myogenesis, and neurogenesis. In mammals, four Notch homologs (Notch 1 to 4) and five ligands (DLL 1, 3 and 4, Jagged 1 and 2) have been identified. DLL-4 is the only Notch ligand expressed predominantly by the vascular endothelium,  making it critical in vascular development.  The mature extracellular domain (ECD) of human DLL4 shares 86% amino acid sequence identity with mouse DLL4.  The use of DLL4, in conjunction with VCAM1, has been shown as an effective method for generating hematopoietic progenitors and T cells from hPSCs in a serum- and feeder-free environment.